Target

Example of drugs

Promising data?

EGFR TK

Gefitinib Erlotinib

Yes, in patients with EGFR mutation.

IGFR TK

AMG 479 BMS-754807

None yet. Further trial results awaited.

c-kit receptor TK

Imatinib

None yet. High study variability of c-kit mutation rate.

c-MET receptor TK

AMG 102

None yet. Trial results awaited.

Farnesyltransferase

Tipifarnib

None yet.

Src kinase

Dasatinib

None yet.

mTOR

Everolimus Temsirolimus

Limited. Trial results awaited.

PI3K

PF-4989216

No trial data.

PARP

Olaparib

Trial recently commenced.

Hh

Vismodegib

No trial data.

VEGF

Bevacizumab Cediranib Vandetanib Aflibercept

Some potential in advanced disease with bevacizumab. Aflibercept trial ongoing.

MMPs

Marimastat Tanomastat

No benefit.

Thalidomide

Therapeutic benefit in phase III trial but dose limited by significant toxicity [thrombotic events].

PDGFR

Sorafenib Sunitinib

Sorafenib—none yet. Sunitinib-progression free survival, other trials ongoing.

Bcl-2

AT-101 ABT-737 Obatoclax

None yet.

Proteosome

Bortezomib

None yet

PLK1

Bi2536

None yet

HDAC

Vorinostat Belinostat

Yes in animal studies, no clinical trial data yet.

Multi-drug resistance proteins

Biricodar

None yet

HER2

Trastuzumab

No trial data.

CD56

BB-10901

Early phase studies promising

GD3

BEC2

None yet.

P53

Vaccine

May indicate chemotherapy responsiveness, but unclear if causative.

CTLA-4

Ipilimumab

Trial awaited.